Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
出版年份 2011 全文链接
标题
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
作者
关键词
-
出版物
ACTA ONCOLOGICA
Volume 51, Issue 2, Pages 234-242
出版商
Informa UK Limited
发表日期
2011-10-21
DOI
10.3109/0284186x.2011.619568
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer
- (2017) Kristoffer Staal Rohrberg et al. Cancer Biomarkers
- Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
- (2011) Finn Ole Larsen et al. ACTA ONCOLOGICA
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
- (2011) Roy S Herbst et al. LANCET
- First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
- (2010) A.-M. C. Dingemans et al. ANNALS OF ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer
- (2009) CHARLOTTE ELBERLING ALMASI et al. APMIS
- Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer
- (2009) A F Lomholt et al. BRITISH JOURNAL OF CANCER
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
- (2009) G. N. Naumov et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- (2009) Helena Linardou et al. Nature Reviews Clinical Oncology
- More is less—combining targeted therapies in metastatic colorectal cancer
- (2009) Cornelis J. A. Punt et al. Nature Reviews Clinical Oncology
- Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
- (2009) Axel Grothey et al. Nature Reviews Clinical Oncology
- Regulation of cell signalling by uPAR
- (2009) Harvey W. Smith et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
- (2008) David M. Jackman et al. CANCER
- Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
- (2008) J. M.L. Ebos et al. CANCER RESEARCH
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
- Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer
- (2008) E. Henic et al. CLINICAL CANCER RESEARCH
- Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells
- (2008) Marianela Perez-Torres et al. EXPERIMENTAL CELL RESEARCH
- Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer
- (2008) Morten et al. Frontiers in Bioscience-Landmark
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
- (2008) Giampaolo Tortora et al. Nature clinical practice. Oncology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started